F-star Therapeutics, Inc.
FSTXDelisted Mar 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001566373
F-star Therapeutics, Inc. was delisted on Mar 9, 2023; its insiders filed their last Form 4 on Mar 9, 2023; 59 institutions reported holding it in 13F filings for Q4 2022, worth $57.8M in total; Fairfax Financial was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 59
- Q4 2022, +6 vs. previous quarter
- 13F value
- $57.8M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 1
- At the end of Q4 2022
Superinvestors holding FSTX, Q4 2022
1 superinvestor reports holding F-star Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Fairfax Financial
Prem Watsa
<0.1%
F-star Therapeutics, Inc.'s share of the portfolio
- Shares
- 49,399
- Value
- $311.7K
Latest insider trades
Open-market purchases and sales by F-star Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2021 (view filing) | Nov 2 | 2 days | Kayitalire LouisChief Medical Officer | SSale | −64 | $6.83 | −$436.84 | −0.1%54.3K after | 2 lots |
| Oct 6, 2021 (view filing) | Oct 4 | 2 days | Kayitalire LouisChief Medical Officer | SSale | −64 | $7.23 | −$462.72 | −0.1%54.3K after | |
| Jul 7, 2021 (view filing) | Jul 2 | 5 days | Kayitalire LouisChief Medical Officer | SSale | −1.05K | $8.43 | −$8.89K | −1.9%54.4K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in F-star Therapeutics, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 1,000,000 | $6.32M | 0.17% | +1,000,000 | New |
| Rock Springs Capital Management LP | 751,889 | $4.75M | 0.11% | 00.0% | Unchanged |
| Trium Capital LLP | 679,744 | $4.30M | 1.97% | +679,744 | New |
| Atlas Venture Life Science Advisors, LLC | 599,524 | $3.79M | 0.46% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 576,881 | $3.65M | 1.03% | 00.0% | Unchanged |
| Atlas Venture Advisors, Inc. | 574,996 | $3.63M | 1.25% | 00.0% | Unchanged |
| Weiss Asset Management LP | 548,189 | $3.46M | 0.17% | +548,189 | New |
| Russell Investments Group, Ltd. | 432,125 | $2.73M | 0.01% | −58,587−11.9% | Reduced |
| Crystalline Management Inc. | 375,000 | $2.37M | 1.19% | +375,000 | New |
| BlackRock Inc. | 297,433 | $1.88M | 0.00% | −370−0.1% | Reduced |